Filgrastim alone and sequential sargramostim and filgrastim have been shown to be more effective than sargramostim alone in the mobilization of CD34 + cells after myelosuppressive chemotherapy (MC). We sought to compare costs and resource use associated with these regimens. Data were collected prospectively alongside a multicenter, randomized trial of filgrastim, sargramostim, and sequential sargramostim and filgrastim. Direct medical costs were calculated for inpatient and outpatient visits and procedures, including administration of growth factors and MC. We followed 156 patients for 30 days or until initiation of high-dose chemotherapy. The main outcome measures were resource use and costs of inpatient and outpatient visits, platelet and red blood cell transfusions, antibiotic use, and apheresis procedures. Hospital admissions, red blood cell transfusions, and use of i.v. antibiotics were significantly more common in the sargramostim group than in the other treatment arms. In univariate and multivariable analyses, total costs were higher for patients receiving sargramostim alone than for patients in the other groups. Mean costs in multivariable analysis for the filgrastim and sequential sargramostim and filgrastim arms were not significantly different. Administration of colony-stimulating factors after myelosuppressive chemotherapy (MC) has been shown to enhance neutrophil recovery and facilitate collection of peripheral blood stem cells (PBSCs) for the support of patients who are planned to receive high-dose chemotherapy.
Administration of colony-stimulating factors after myelosuppressive chemotherapy (MC) has been shown to enhance neutrophil recovery and facilitate collection of peripheral blood stem cells (PBSCs) for the support of patients who are planned to receive high-dose chemotherapy. [1] [2] [3] [4] The combination of MC and a colony-stimulating factor yields significantly higher numbers of PBSCs, as measured by CD34
+ cell count, than either MC alone or colony-stimulating factor alone. 1 As a result, it is now standard practice to administer disease-specific MC, followed by a colonystimulating factor, to facilitate neutrophil recovery, collect optimal numbers of CD34 + PBSCs, and more safely and effectively treat the associated malignancy. 1 Several studies suggest that the two most commonly used colony-stimulating factors in the United States, recombinant human granulocyte colony-stimulating factor (filgrastim) [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] and recombinant human granulocytemacrophage colony-stimulating factor (sargramostim), [12] [13] [14] [15] yield high numbers of CD34
+ cells in patients with good bone marrow reserves. Patients receiving these growth factors, especially filgrastim, experience quicker recovery of absolute neutrophil counts, less fever, and fewer hospital admissions, and receive fewer red blood cell transfusions and less i.v. antibiotic therapy. 4, [16] [17] [18] Recently, the relative effectiveness of these growth factors has been examined more carefully. A randomized, phase III clinical trial has demonstrated that both filgrastim alone and sequential administration of sargramostim and filgrastim are superior to sargramostim alone for optimal mobilization of CD34 + cells, requiring fewer apheresis procedures and fewer days of growth factor administration. 19 Although the clinical benefit of these therapies has been demonstrated, the associated costs and resource use have not been evaluated thoroughly.
Economic evaluations of new medical therapies have become increasingly important in oncology. The estimated costs of cancer treatment in the United States have risen dramatically in the past decade owing to both the aging of the population and the increasing use of more resourceintensive therapies, including hematopoietic stem cell transplantation. [20] [21] [22] When medical therapies are costly and health care resources scarce, economic evaluations can provide useful information to guide clinical decision making about allocation of resources. 23 In this economic evaluation of a recent multicenter, randomized, open-label clinical trial, we evaluated the costs and resource use associated with administration of three regimens of colony-stimulating factor after mobilization chemotherapy. The clinical results of the trial have been reported previously.
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Patients and methods
Overview of the clinical trial
The open-label randomized trial of three schedules of myeloid growth factors administered after MC was conducted from September 1997 to July 1998 at 39 medical centers in the United States. The study compared the effects of filgrastim, sargramostim, and sequential sargramostim and filgrastim on CD34 + cell yields and morbidity after MC. The trial recruited 158 patients with multiple myeloma, malignant lymphoma, or breast cancer. MC consisted of cyclophosphamide 4 g/m /day for 5 days followed by filgrastim 6 g/kg/day. All regimens were administered daily until the final day of apheresis. The primary endpoints of the clinical study included time to hematologic recovery, CD34
+ cell yield, and morbidity after administration of MC.
Compared with those who received sargramostim, patients who received filgrastim had faster recovery of absolute neutrophil count у0.5 × 10 9 /l (median, 11 vs 14 days; P = 0.0001). In addition, patients who received filgrastim yielded more CD34 + cells (median, 7.1 vs 2.0 × 10 6 /kg/apheresis; P = 0.0001) and achieved у2.5 × 10 6 (94% vs 78%; P = 0.021) and у5 × 10 6 (88% vs 53%; P = 0.001) CD34
+ cells/kg with fewer apheresis procedures (median, 2 vs 3; P = 0.002) and fewer days of growth factor treatment (median, 12 vs 14; P = 0.0001). There were no major differences in outcomes between the filgrastim and sequential regimens. Complete results from the clinical trial are reported elsewhere. 19 
Parallel economic evaluation
Resource use and associated costs were monitored for 156 of the 158 patients enrolled in the clinical trial. Two patients from the sargramostim arm were excluded from analysis because they received the wrong growth factor regimen. Another six patients did not have PBSCs harvested because of either early treatment-related death or poor clinical condition, but data collected for these six patients prior to dropout were included in the economic analysis. The primary economic endpoint was total cost per patient for a period of 30 days or until the initiation of high-dose chemotherapy.
Data collection
Data on resource use were collected prospectively for each patient for the following variables: antibiotics (oral ciprofloxacin as prophylaxis, i.v. broad-spectrum antibiotics for febrile patients), days in the hospital, platelet transfusions, red blood cell transfusions, colony-stimulating factor administrations, and apheresis procedures.
Cost estimates
Costs for inpatient and outpatient services were developed for each resource category from the provider perspective and are expressed in 1998 US dollars. The cost of a hospital inpatient day was estimated to be $2181.66, based on mean costs calculated from one university hospital's cost accounting system for 52 patients undergoing PBSC transplantation. Blood products and antibiotics were counted separately and are not reflected in the mean costs of hospital stays. Costs of blood products were based on average acquisition costs per unit plus the administration costs of transfusions. The cost of platelet transfusion was $527.37, the cost of red blood cell transfusion was $421.90, and the cost of apheresis was $2390.06. Costs of antibiotics were based on the average wholesale price for the generic product plus administration costs, and were calculated according to average daily dose requirements for a 70 kg person with normal renal function. The cost of i.v. antibiotics was estimated at $114.39 per day, and the cost of amphotericin B was $20.89 per day.
Growth factor administration costs were based on the average wholesale price of filgrastim 6 g/kg/day and sargramostim 250 g/kg/day. The price of filgrastim was $256.90 per dose, and the price of sargramostim was $252.06 per dose. The costs of sequential administration of sargramostim and filgrastim ($254.48) were calculated as an average of the administration costs of filgrastim alone and sargramostim alone. MC costs were based on the average wholesale price of the specified regimen plus the costs of administration, which were obtained from the Medicare Fee Schedule. Recommended doses and standard frequencies were based on each patient's body surface area.
Statistical analysis
All data were collected using a custom-designed distributed data system, which was reviewed at a central clinical trial center and analyzed using the SAS statistical software package (SAS Institute, Cary, NC, USA). For each of the treatment groups, we reported means (continuous variables) and proportions (categorical variables) of baseline patient characteristics and resources used. To test for differences among treatment groups, t-tests or analysis of variance were used for continuous variables, and 2 or Fisher exact tests were used for categorical variables. All tests were twosided and were considered statistically significant at P р 0.05.
We analyzed costs using both univariate and multivariable analysis. To test for differences in mean costs across treatment groups, pairwise t-tests were used. To assess treatment group differences after controlling for patient dif-ferences in baseline clinical and demographic covariates, costs were also analyzed using ordinary least squares regression with stepwise variable selection. Candidate clinical and demographic covariates included age, sex, diagnosis, and prior radiation therapy. Because cost distributions tend to be skewed, models were estimated using both log-transformed and untransformed cost data as the dependent variable. As no significant differences with respect to r 2 and the distribution of residuals were found, the untransformed and transformed data were judged comparable and untransformed cost data were reported. Finally, we explored the robustness of the results through univariate sensitivity analysis in which costs for selected individual resource categories were multiplied by factors of 2 and 0.5.
Results
Patient characteristics
Baseline characteristics of the 156 patients randomized to receive one of the three growth factor regimens are shown in Table 1 . There were no statistically significant differences among the patients in the three groups.
Resource use
Resource use for each arm of the study is presented in Table 2 . The incidence of i.v. antibiotic use was 69% in the sargramostim group, as compared to 27% for filgrastim alone (P = 0.001) and 25% for the sequential regimen (P = 0.001). The proportion of patients admitted to the hospital was significantly higher for the sargramostim group (43%) than for either filgrastim alone (24%, P = 0.013) or the sequential regimen (23%, P = 0.017). In addition, 48% of patients in the sargramostim group received red blood cell transfusions, as compared to 22% of patients in the Bone Marrow Transplantation filgrastim group (P = 0.006) and 36% of patients in the sequential regimen group (P = 0.116). The mean number of days of growth factor administration was significantly higher for patients in the sargramostim group (14.1 vs 11.9 for filgrastim alone (P = 0.006) and 12.8 for the sequential regimen (P = 0.075), as were the mean number of apheresis procedures performed (2.9 vs 2.1 for filgrastim alone (P = 0.005) and 2.3 for the sequential regimen (P = 0.039)).
Costs
Results of the univariate analysis of costs are presented in Table 3 Controlling for age and prior chemotherapy, the total mean adjusted cost for the sargramostim group was $21 347, as compared to $15 406 for filgrastim (P = 0.001) and $15 975 for the sequential regimen (P = 0.002). Table 4 displays the results of the univariate sensitivity analysis of selected resource costs. Again, the results mirror earlier findings. Specifically, multiplying selected individual resource categories by factors of 2.0 and 0.5 did not change the magnitude of the results in any meaningful way, suggesting that the findings are robust. a Values are expressed as mean (standard deviation) unless otherwise indicated. *P р 0.05 for comparison between filgrastim alone and sargramostim alone. **P р 0.05 for comparison between sargramostim alone and sequential sargramostim and filgrastim. RBC = red blood cell.
Discussion
In this paper, we present the results of an economic evaluation of filgrastim, sargramostim, and sequential sargramostim and filgrastim administered after MC. We found that administration of filgrastim alone or sequential sargramostim and filgrastim for the prevention of neutropenia and the mobilization of stem cells into the peripheral blood for collection was cost-saving compared to the administration of sargramostim alone. We previously reported that filgrastim was more efficacious than sargramostim. 19 Specifically, mean total costs for administration of filgrastim alone were $5429 less than the mean total costs of sargramostim alone (P = 0.002); the difference between mean total costs of sargramostim alone and sequential sargramostim and filgrastim was $4884 (P = 0.007). Filgrastim did not yield significant cost savings when compared to the sequential sargramostim and filgrastim regimen.
Although the clinical benefit of colony-stimulating factors after MC has been demonstrated, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] the relative costs and resource use associated with specific growth factors have not been evaluated thoroughly. An earlier study by Jansen et al 24 compared filgrastim (5 g/kg/day) and sargramostim (500 g/day) following autologous PBSC transplantation in 52 patients with metastatic (stage IV) or locally advanced (stage II or III) breast cancer. While neutropenic recovery occurred more quickly in the filgrastim group, the use of red blood cells (2.8 vs 2.3 units) and platelet transfusions (2.5 vs 3.1) was similar for the two groups, as was the use of i.v. antibiotics (4.3 vs 4.6 days). Analysis of a limited set of resource costs suggested no significant differences between the two treatments. The dif- ference in findings between Jansen et al's study and the one reported here may reflect lack of randomization to treatment arms, analysis of only a limited set of costs, and a small sample size in the Jansen paper. 24 The results raise the question of whether delayed administration of filgrastim may, in fact, be crucial to the mobilization of stem cells into the peripheral blood for collection. That is, the favorable findings regarding the filgrastim and sequential regimens may suggest that the last 5 days of filgrastim comprise the crucial component of the mobilization schedule, not the first 6 days of either filgrastim or sargramostim. Unfortunately, the clinical trial was not designed to address this possibility.
Resource costs were estimated and not directly observed in this study. The cost of a hospital stay, for example, was estimated from one university hospital's cost accounting system but applied to patients at all study sites. While the cost estimate may not be representative of all hospitals in the study, the estimation of resource costs is unlikely to affect the results in a meaningful way because the treatment groups are balanced. The results of the sensitivity analysis confirm, moreover, that the findings are robust even when specific cost assumptions vary.
In addition, because the cost estimates were based on data gathered as part of a clinical trial, protocol-induced costs may exert an upward bias on our cost estimates. However, it is unlikely that protocol-induced costs affected one treatment arm differentially, so the relative cost of the three treatments should not reflect that bias. Further, this protocol did not alter clinical practice in any meaningful way other than through growth factor administration.
In this economic evaluation of a recent multicenter, randomized, open-label trial, we evaluated the costs and resource use associated with administration of three regimens of colony-stimulating factor after MC. Hospital admissions, red blood cell transfusions, and use of i.v. antibiotics were significantly more common among patients receiving sargramostim alone than among patients in other treatment arms. In univariate and multivariate analyses, total costs were higher for patients receiving sargramostim alone than for patients in the other groups. In conclusion, Bone Marrow Transplantation filgrastim alone and sequential sargramostim and filgrastim are less costly than sargramostim alone after myelosuppressive chemotherapy, as well as therapeutically more beneficial.
